Matched cohort study on the efficacy of tocilizumab in patients with COVID-19

Rodríguez‐Molinero, Alejandro; Pérez-López, Carlos; Gálvez‐Barrón, César; Miñarro, Antonio; Macho, Oscar; López, Gabriela F.; Robles, Maria Teresa; Dapena, María Dolores; Martínez, Santiago; Rodríguez, Ezequiel; Pérez, Isabel; Casas, Anna Alberti; Garcia, Jose L. Avalos; Ruiz, Manel Borrego; Carrasco, Gemma Añaños; Pisa, Pedro L. Campo; Fornerino, Ana M. Capielo; Pastilla, Antonio Chamero; Artés, Andreu Fenollosa; Ambros, Clara Gris; Martinez, Lourdes Hernandez; García, Antonio Hidalgo; Puig, Mireia; Ràfols, Núria Milà; Hinojosa, José C. Molina; Mónaco, Ernesto E.; Fonollosa, Laura Peramiquel; Zambrano, Italo G. Pisani; Rives, Juan P.; Bach, Enric Sabria; Rodriguez, Yris M. Sanchez; Martin, Maria del Mar Segura; Llurba, Gemma Tremosa; Gili, Ester Ventosa; Cabanellas, Florencia I. Venturini; Meler, Natàlia Vidal

doi:10.1016/j.onehlt.2021.100214

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Rodríguez-Molinero et al . 20 believed that an early intervention of GM-CSF antibodies also triggers adverse events in COVID-19 patients. Kimmig et al .…”

Section: Discussionmentioning

confidence: 99%

“…However, the ICU admission rate of COVID-19 patients has been rarely reported. In the included studies, Martínez-Sanz et al 19 20 believed that an early intervention of GM-CSF antibodies also triggers adverse events in COVID-19 patients. Kimmig et al 21 and Quartuccio et al 22 revealed that COVID-19 patients in the GM-CSF antibody group have a higher rate of secondary infection.…”

Section: Discussionmentioning

confidence: 99%

“…COVID-19 progressively causes severe respiratory failure and serious inflammation; as a result, this leads to a high mortality risk. However, Rodríguez-Molinero et al 20 believed that an early intervention of GM-CSF antibodies also triggers adverse events in COVID-19 patients. Kimmig et al 21 and Quartuccio et al 22 revealed that COVID-19 patients in the GM-CSF antibody group have a higher rate of secondary infection.…”

Section: R E T R a C T E Dmentioning

confidence: 99%

See 2 more Smart Citations

RETRACTED: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

Guan

Wang

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

August 2021. When re-examined, the authors noted that they had mistakenly included several studies evaluating the role of IL-6 inhibitors and concluded that they needed to do an updated search and analysis https:// journals.sagepub.com/doi/full/10.1177/20406223211055922. For this reason, the article has been retracted and will be republished, if appropriate, following additional peer review of the new data.

show abstract

“…However, Rodríguez-Molinero et al . 20 believed that an early intervention of GM-CSF antibodies also triggers adverse events in COVID-19 patients. Kimmig et al .…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: R E T R a C T E Dmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

Guan

Wang

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Regarding these other studies, it is noteworthy that evidence is beginning to accumulate with prospective clinical trials, some of them randomized. Sabbatinelli et al, Hermine et al, Salvarani et al, Malekzadeh et al, Dastan et al and Rodríguez-Molinero et al have all addressed the question of Interleukin 6 inhibitor and the outcomes on severe or critical COVID-19 patients [ 54 , 55 , 56 , 57 , 58 , 59 ]; amongst them two studies found clinical results that favors the intervention groups with Tocilizumab, while two are descriptive with no comparator and two showed no difference with the intervention.…”

Section: Resultsmentioning

confidence: 99%

“…Regarding these other studies, it is noteworthy that evidence is beginning to accumulate with prospective clinical trials, some of them randomized. Sabbatinelli [54][55][56][57][58][59]; amongst them two studies found clinical results that favors the intervention groups with Tocilizumab, while two are descriptive with no comparator and two showed no difference with the intervention.…”

Section: Interleukin 6 Inhibitorsmentioning

confidence: 99%

Biologics in COVID-19 So Far: Systematic Review

et al. 2022

View full text Add to dashboard Cite

This systematic review aimed to reevaluate the available evidence of the use of biologics as treatment candidates for the treatment of severe and advanced COVID-19 disease; what are the rationale for their use, which are the most studied, and what kind of efficacy measures are described? A search through Cochrane, Embase, Pubmed, Medline, medrxiv.org, and Google scholar was performed on the use of biologic interventions in COVID-19/SARS-CoV-2 infection, viral pneumonia, and sepsis, until 11 January 2022. Throughout the research, we identified 4821 records, of which 90 were selected for qualitative analysis. Amongst the results, we identified five popular targets of use: IL6 and IL1 inhibitors, interferons, mesenchymal stem cells treatment, and anti-spike antibodies. None of them offered conclusive evidence of their efficacy with consistency and statistical significance except for some studies with anti-spike antibodies; however, Il6 and IL1 inhibitors as well as interferons show encouraging data in terms of increased survival and favorable clinical course that require further studies with better methodology standardization.

show abstract

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update

Tleyjeh

Kashour

Riaz

et al. 2021

Clinical Microbiology and Infection

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Matched cohort study on the efficacy of tocilizumab in patients with COVID-19

Cited by 6 publications

References 15 publications

RETRACTED: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

RETRACTED: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

Biologics in COVID-19 So Far: Systematic Review

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update

Contact Info

Product

Resources

About